Estimate feature incremental value
Estimate rollout value from segment-level treated/control outcomes with beta-binomial uplift posteriors, finance-owned contribution economics, and a probability-of-positive-value gate.
What it's for
Translates feature experiment outcomes into a posterior distribution of incremental financial value rather than celebrating uplift without economics.
What you give it
Inputs split into evidence read from your connected systems, calibration your team owns, and numerical controls that affect precision but never the result's meaning.
| Field | Type | Role | Required |
|---|---|---|---|
| beta_prior_alpha | number > 0 | Your calibration | Optional |
| beta_prior_beta | number > 0 | Your calibration | Optional |
| confidence_level | number ≥ 0.5, ≤ 0.999 | Your calibration | Optional |
| max_detail_rows | integer ≥ 1, ≤ 500 | Numerical control | Optional |
| minimum_probability_positive_value | number ≥ 0, ≤ 1 | Your calibration | Optional |
| posterior_draws | integer ≥ 1000, ≤ 200000 | Numerical control | Optional |
| rollout_cost | number ≥ 0 | Your calibration | Yes |
| seed | integer ≥ 0, ≤ 4294967295 | Numerical control | Optional |
| segments | array of objects (7 fields) | Evidence | Yes |
Each segments
record
| Field | Type | Required |
|---|---|---|
| contribution_value_per_conversion | number | Yes |
| control_successes | integer (≥ 0) | Yes |
| control_trials | integer (≥ 1) | Yes |
| eligible_accounts | number (≥ 0) | Yes |
| id | string (non-empty) | Yes |
| treated_successes | integer (≥ 0) | Yes |
| treated_trials | integer (≥ 1) | Yes |
{
"minimum_probability_positive_value": 0.8,
"posterior_draws": 5000,
"rollout_cost": 75000,
"seed": 17,
"segments": [
{
"contribution_value_per_conversion": 240,
"control_successes": 120,
"control_trials": 1000,
"eligible_accounts": 8000,
"id": "small-business",
"treated_successes": 160,
"treated_trials": 1000
},
{
"contribution_value_per_conversion": 900,
"control_successes": 84,
"control_trials": 600,
"eligible_accounts": 2000,
"id": "mid-market",
"treated_successes": 105,
"treated_trials": 600
}
]
} What you get back
This is the actual output of running the example above — computed by the same function the platform calls, not an illustration.
{
"assumptions": [
"Treatment/control counts come from a valid randomized or conditionally exchangeable design with stable exposure, no material interference, complete outcome maturity, and consistent segment membership.",
"Eligible accounts, contribution per conversion, and rollout cost are incremental finance-owned quantities over one horizon without cross-segment double counting.",
"Beta-binomial uncertainty covers conversion sampling only; adoption, duration, cannibalization, treatment heterogeneity beyond segments, and causal-design error require additional modeling."
],
"configuration": {
"beta_prior_alpha": 1,
"beta_prior_beta": 1,
"confidence_level": 0.9,
"minimum_probability_positive_value": 0.8,
"posterior_draws": 5000,
"seed": 17
},
"decision": "feature_incremental_value_supported",
"method": "beta_binomial_segment_feature_incremental_value_v1",
"segment_diagnostics": [
{
"expected_incremental_value_before_rollout_cost": 77066.5402,
"posterior_mean_uplift": 0.0401,
"probability_positive_segment_value": 0.9934,
"probability_positive_uplift": 0.9934,
"segment_id": "small-business",
"uplift_interval": [
0.0152,
0.0658
]
},
{
"expected_incremental_value_before_rollout_cost": 62968.7665,
"posterior_mean_uplift": 0.035,
"probability_positive_segment_value": 0.946,
"probability_positive_uplift": 0.946,
"segment_id": "mid-market",
"uplift_interval": [
-0.0008,
0.069
]
}
],
"summary": {
"expected_incremental_value": 65035.3067,
"incremental_value_interval": [
-14302.1922, Truncated for display — the full payload is 52 lines.
How it works
Causal inference & experiment design — Separate what a change caused from what merely moved alongside it.
- 1 Freeze randomized or conditionally exchangeable treated/control cohorts, mature conversion outcomes, non-overlapping segments, eligible future accounts, contribution per conversion, and rollout cost.
- 2 Draw treated and control conversion posteriors per segment, propagate uplift through eligible accounts and contribution, aggregate segments, subtract rollout cost, and report the value interval and probability positive.
- 3 Approve value only after the governed probability gate and separate checks for assignment integrity, interference, attrition, exposure maturity, cannibalization, and transport to the rollout population.
Before you trust it
Every tool in the catalog ships with the conditions under which its answer is meaningful — and the conditions under which it should abstain instead of guessing.
Assumptions & guardrails
- Assignment or adoption timing, interference policy, overlap, attrition, and outcome availability match the estimand encoded by the method.
- Treatment assignment is valid or conditional exchangeability is defensible, outcomes are mature, interference is immaterial, and segment/account/value definitions avoid double counting.
- A causal label is warranted only when design and diagnostic requirements pass; otherwise treat the result as descriptive or abstain.
- Beta-binomial intervals cover conversion sampling only; they do not absorb design bias, duration, cannibalization, adoption decay, or extrapolation error.
Minimum evidence
- segments: required and organization-defined
- rollout_cost: required and organization-defined
How to validate it
Preserve the assignment/adoption design and validate overlap, pre-period or placebo diagnostics, attrition, interference policy, and cluster-level uncertainty; never tune on the estimated effect.
Calibrating it to your org
Same for everyone
The mathematical kernel, validation rules, method version, and JSON output semantics are organization-independent; no tenant-trained coefficients or company benchmark is embedded in the function.
Specific to you
- treated/control trials and successes by pre-treatment segment with point-in-time outcome maturity
- experiment estimand, assignment integrity, exclusion/attrition policy, outcome window, interference checks, segment freeze, rollout population, contribution/cost horizon, priors, and probability gate
Calibration workflow
- 1 Define the management decision, target outcome, aggregate unit, privacy boundary, cadence, and prediction/intervention horizon for this organization.
- 2 Build a tenant-scoped historical cohort using only information available before each prediction or decision; preserve zero periods, censoring, assignment probabilities, and unresolved outcomes when the method requires them.
- 3 Estimate statistical parameters on training history, but obtain costs, utilities, risk tolerance, practical-effect thresholds, capacity, and policy constraints from accountable decision owners.
- 4 Validate on later time windows or held-out aggregate units at the deployment grain, against a simple baseline and the function-specific validation strategy.
- 5 Deploy only if the returned decision clears evidence, overlap, calibration, robustness, and guardrail checks; warning, unsupported, schema-gap, and fallback decisions are abstentions.
- 6 Monitor realized outcomes, data drift, coverage, and decision regret; recalibrate at a governed cadence or after a detected regime/definition change, never merely because a stakeholder dislikes the result.
Call it from your AI
You don't wire up 388 tools in your MCP client. The GitRevio MCP server exposes 18 tools, three of which let an agent search the catalog, read a tool's schema, and run it — so the assistant finds this one on its own.
gitrevio_capabilities_search
{ "q": "estimate rollout value from segmentlevel treatedcontrol" }
→ finds "estimate_feature_incremental_value"
gitrevio_capability_describe
{ "capability_id": "estimate_feature_incremental_value" }
→ returns the input schema and agent guidance shown on this page
gitrevio_capability_run
{ "capability_id": "estimate_feature_incremental_value", "arguments": { ... } }
→ returns the result shown above Works in Claude Desktop, Claude Code, Cursor, Cline, Continue.dev, Goose and Aider. See the MCP server.
Related tools
Estimate pricing experiment value
Choose pricing experiment arms by posterior future contribution, conversion-harm probability, and a model-conditional perfect-information value upper bound.
Rank features by evidence adjusted ROI
Rank feature investments by reliability-shrunk ROI, downside probability, and CVaR using aligned outcome scenarios and an explicit skeptical prior.
Audit recurring revenue bridge integrity
Audit recurring revenue as a continuous stock/flow ledger: reconcile opening revenue through new, expansion, reactivation, contraction, churn, FX and acquisition/divestiture movements to closing revenue; require each next opening to equal the prior close; and recompute GRR and NRR on an organic existing-customer perimeter that cannot be inflated by new business, reactivation, FX or M&A.
Calculate churn prevention break even
Calculate the absolute churn reduction an intervention must cause to break even, then test aligned baseline/treated scenarios against probability-of-positive-value and portfolio CVaR gates.
Calculate procurement negotiation range
Calculate an uncertainty-aware procurement bargaining zone from independently governed buyer and supplier BATNA economics; protect both reservation prices at explicit confidence levels, derive a bargaining-weight target, quantify ZOPA probability and tail overpayment, and abstain when evidence cannot support an overlap.
Estimate cannibalization adjusted feature value
Estimate feature value after posterior cannibalization of legacy contribution, using aligned adoption scenarios, beta-binomial substitution uncertainty, and value plus substitution-risk gates.